Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter D Cole

Showing results (61-70 of 106) with videos related to

Pageof 11
Sort By:
The Lancet. Oncology|August 21, 2018
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trialPeter D Cole, Kathleen M McCarten, Qinglin Pei, et al.
International Journal of Radiation Oncology, Biology, Physics|November 12, 2021
Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology GroupRahul R Parikh, Kara M Kelly, David C Hodgson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2024
Exposure-Response and Subgroup Analyses to Support Body Weight-Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin LymphomaZufei Zhang, Daping Zhang, Wenchuan Guo, et al.
Pediatric Blood & Cancer|May 27, 2023
Prognostic value of chest x-ray- and CT-defined large mediastinal adenopathy in high-risk pediatric Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0831Andrea C Lo, Inki Lee, Qinglin Pei, et al.
Pediatric Blood & Cancer|December 9, 2024
Feasibility of Utilizing a Brief Neurocognitive Battery in 3-Year-Old Patients During Treatment for Acute Lymphoblastic LeukemiaSameera Ramjan, Peter D Cole, Melanie Blair-Thies, et al.
Pediatric Blood & Cancer|January 10, 2026
Trajectory of Neurocognitive Functioning in Children Treated for Acute Lymphoblastic Leukemia (ALL): Dana-Farber Cancer Institute ALL Consortium Study 16-001Alexandra Thrope, Sameera Ramjan, Charlie White, et al.
Journal of Pediatric Health Care : Official Publication of National Association of Pediatric Nurse Associates & Practitioners|July 28, 2016
How Variable Is Our Delivery of Information? Approaches to Patient Education About Oral Chemotherapy in the Pediatric Oncology ClinicJustine M Kahn, Uma H Athale, Luis A Clavell, et al.
British Journal of Haematology|March 15, 2023
Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group studySarah A Milgrom, Jihyun Kim, Qinglin Pei, et al.
Pediatric Blood & Cancer|May 14, 2025
Baseline Neurocognitive Functioning Among Children Treated for Acute Lymphoblastic Leukemia (ALL): Dana Farber Cancer Institute ALL Consortium Study 16-001Sameera Ramjan, Melanie Blair Thies, Yuelin Li, et al.
Cancer|February 11, 2004
Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemiaYotam Kaufman, Stavit Drori, Peter D Cole, et al.
Pageof 11

Showing results (61-70 of 106) with videos related to

Sort By:
Pageof 11
The Lancet. Oncology|August 21, 2018
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trialPeter D Cole, Kathleen M McCarten, Qinglin Pei, et al.
International Journal of Radiation Oncology, Biology, Physics|November 12, 2021
Patterns of Initial Relapse from a Phase 3 Study of Response-Based Therapy for High-Risk Hodgkin Lymphoma (AHOD0831): A Report from the Children's Oncology GroupRahul R Parikh, Kara M Kelly, David C Hodgson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2024
Exposure-Response and Subgroup Analyses to Support Body Weight-Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin LymphomaZufei Zhang, Daping Zhang, Wenchuan Guo, et al.
Pediatric Blood & Cancer|May 27, 2023
Prognostic value of chest x-ray- and CT-defined large mediastinal adenopathy in high-risk pediatric Hodgkin lymphoma: A report from the Children's Oncology Group Study AHOD0831Andrea C Lo, Inki Lee, Qinglin Pei, et al.
Pediatric Blood & Cancer|December 9, 2024
Feasibility of Utilizing a Brief Neurocognitive Battery in 3-Year-Old Patients During Treatment for Acute Lymphoblastic LeukemiaSameera Ramjan, Peter D Cole, Melanie Blair-Thies, et al.
Pediatric Blood & Cancer|January 10, 2026
Trajectory of Neurocognitive Functioning in Children Treated for Acute Lymphoblastic Leukemia (ALL): Dana-Farber Cancer Institute ALL Consortium Study 16-001Alexandra Thrope, Sameera Ramjan, Charlie White, et al.
Journal of Pediatric Health Care : Official Publication of National Association of Pediatric Nurse Associates & Practitioners|July 28, 2016
How Variable Is Our Delivery of Information? Approaches to Patient Education About Oral Chemotherapy in the Pediatric Oncology ClinicJustine M Kahn, Uma H Athale, Luis A Clavell, et al.
British Journal of Haematology|March 15, 2023
Baseline metabolic tumour burden improves risk stratification in Hodgkin lymphoma: A Children's Oncology Group studySarah A Milgrom, Jihyun Kim, Qinglin Pei, et al.
Pediatric Blood & Cancer|May 14, 2025
Baseline Neurocognitive Functioning Among Children Treated for Acute Lymphoblastic Leukemia (ALL): Dana Farber Cancer Institute ALL Consortium Study 16-001Sameera Ramjan, Melanie Blair Thies, Yuelin Li, et al.
Cancer|February 11, 2004
Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemiaYotam Kaufman, Stavit Drori, Peter D Cole, et al.
Pageof 11